Bayer AG announces a $2.2 billion investment to build a new pharmaceutical manufacturing facility in New Albany, Ohio, aiming to double its United States sales by 2030. The site, scheduled to begin drug substance production in 2031 and finished product manufacturing in 2034, will create 600 permanent jobs. This expansion comes as European drugmakers face pressure from the Trump administration to lower prescription prices and boost domestic manufacturing.
Bayer's investment strategy
- ▪Bayer AG announced plans on October 2, 2026, to invest $2.2 billion to build a new pharmaceutical manufacturing site in New Albany, Ohio
- ▪Bayer AG pharmaceuticals unit Chief Operating Officer Sebastian Guth stated that the $2.2 billion Ohio investment is a deliberate decision to strengthen Bayer AG's presence in the United States alongside its presence in Europe and Asia
Medicines to be produced at the site
- ▪Bayer AG's planned $2.2 billion facility in New Albany, Ohio will manufacture medicines for cancer, cardiovascular, and kidney diseases
- ▪Key products underpinning Bayer AG's expansion include the chronic kidney disease treatment Kerendia, prostate cancer drug Nubeqa, and stroke-prevention drug candidate asundexian
Bayer's United States sales growth
- ▪Bayer AG's pharmaceuticals unit has increased its United States share of global revenue to 35% from 20% in 2018
- ▪Bayer AG's pharmaceuticals unit aims to double its United States sales by the end of the decade, according to Chief Operating Officer Sebastian Guth
Pressure from the Trump administration
- ▪Bayer AG's $2.2 billion investment in a new Ohio manufacturing site comes amid pressure from the administration of President Donald Trump on drugmakers to lower United States prescription medicine prices and boost domestic manufacturing
- ▪President Donald Trump has pressured drugmakers to lower United States prescription medicine prices while demanding that other developed countries increase their prices
Debatable claims
- ▪Bayer's decade-long construction timeline is too slow to address US drug supply vulnerabilities
- ▪High US drug prices are necessary to attract pharmaceutical manufacturing investment
- ▪European drugmakers' shift of manufacturing to the US undermines European drug security
- ▪Political pressure on foreign drugmakers is an effective way to boost US manufacturing
Story comments
Loading comments…